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Abstract
Congenital adrenal hyperplasia has traditionally been treated with daily oral
doses of glucocorticoids and mineralocorticoid supplements. Such therapy
does not precisely replicate the adrenal cortex's circadian pattern. As a
consequence, patients are intermittently overtreated or undertreated leading to
growth suppression in children, excess weight gain and altered metabolism.
Several new treatments are on the horizon. This article will summarize some
new potential therapies as adjuncts to, or replacement for, standard therapy.
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Introduction
Congenital adrenal hyperplasia (CAH) is caused by one of sev-
eral inherited enzyme deficiencies. The most common form of 
the classic disorder, found in about 1:14,000 to 1:18,000 births, 
is steroid 21-hydroxylase deficiency. Mutations in CYP21A2 
(P450c21) impair adrenocortical production of cortisol and fre-
quently aldosterone and lead to the accumulation of adrenal sex 
steroids1. Allelic variation accounts for most phenotypic 
differences. Cardinal features of classic CAH include atypical 
development of the external genitalia in girls with manifest viri-
lization. Both males and females have salt wasting with failure 
to thrive and potentially fatal hypovolemia and shock. Newborn 
screening, now universal in the US2 and in many developed coun-
tries3, can mitigate these complications (reviewed in 4). Despite 
life-saving glucocorticoid (GC) and mineralocorticoid (MC) oral 
therapies, treatment does not precisely replicate adrenal physi-
ology. Individuals with CAH commonly experience adverse 
outcomes in terms of growth, metabolic, reproductive, and mental 
health endpoints5,6. This discussion of emerging medical treat-
ments will be restricted to the classic or severe forms of steroid 
21-hydroxylase deficiency.
Improved glucocorticoid delivery
Normal adrenocortical secretion has a circadian rhythm quite 
distinct from that of blood cortisol levels achieved by admin-
istering two or three daily oral doses of GC medication7,8. 
Hydrocortisone (HC) subcutaneous delivery for 6 months via 
a programmed pump in eight adults with classic CAH produced 
significant reduction in adrenal androgens with improvement in 
quality of life and fatigue9. Though conceptually attractive and 
perhaps applicable to highly motivated patients who are inad-
equately managed by conventional treatment, pump management 
is complex. An early trial with a once-daily modified-release oral 
HC preparation (Chronocort, Diurnal, Cardiff, UK) given to 
16 adults with classic CAH decreased adrenal androgen pre-
cursors despite a slightly reduced daily HC dose10. However, 
subsequent phase 3 trials apparently failed to demonstrate supe-
riority to standard HC treatment and this potential new treatment 
is currently on hold. A different type of modified-release GC 
(Plenadren, Shire, London, UK) is approved in Europe for 
adrenal insufficiency but has not been formally tested in CAH.
In the US, the lowest-dose HC tablet is 5 mg, and in Europe 
10 mg, excessive for infants and young children. Availability 
of pediatric-dose formulations would eliminate concerns about 
improper compounding of HC from tablets11,12. Based on favora-
ble trial results13, the European Medicines Agency has approved 
very-low-dose HC 1 mg granules (Alkindi, Diurnal) for treat-
ment of adrenal insufficiency or CAH in infants and children. 
A US Food and Drug Administration new drug application is said 
to be pending.
Androgen/estrogen antagonists and synthesis 
inhibitors
To ameliorate the effects of adrenal androgen excess, females 
with CAH often need treatment additional to GC replacement. 
Such treatments may include dermatologic therapies for acne 
and hirsutism or additional hormone treatments (or both) to 
regulate menses or aid conception. All steroidogenic pathways 
to androgens and estrogens depend on activity of the enzyme 
17-hydroxylase/17,20-lyase (P450c17, CYP17A1). Abiraterone 
acetate is an orally active, potent P450c17 inhibitor14 indicated 
for treatment of castration-resistant prostate cancer15,16. Short-
term adjunctive treatment with 250 mg/day abiraterone acetate 
(alongside standard steroid replacement) normalized the pre-
dose serum androstenedione levels in all six women with poorly 
controlled classic CAH17. Because abiraterone acetate also inhib-
its gonadal steroid production and could be teratogenic, its 
use in CAH would be limited to pre-pubertal children, women 
using contraceptives, or men who receive gonadal replace-
ment. A clinical trial is under way in pre-pubertal children with 
CAH (ClinicalTrials.gov Identifier: NCT02574910) with the 
goal of minimizing exogenous GC and endogenous adrenal sex 
steroid hormone exposure in order to normalize growth and 
pubertal development.
Growth-promoting drugs
A systematic review and meta-analysis of adult height in indi-
viduals with classic CAH diagnosed before the age of 5 years 
included just over 1000 children in 35 studies that met the eligi-
bility criteria18. The pooled data indicated a corrected adult height 
standard deviation (SD) of −1.0. The average heights were 169 
cm (66.5 inches) for men and 157 cm (61.8 inches) for women, 
both within the normal range for shorter than average adults in the 
general population. These data obviate the routine use of growth- 
promoting medications that are considered only for individuals 
whose heights were expected to be at least −2.25 SDs. Subgroup 
analysis revealed that the addition of early MC treatment was 
associated with increased height outcome18.
A 2001 report tested growth hormone alone (n = 12) or in com-
bination with leuprolide acetate (n = 8) to enhance growth in 
CAH patients with evidence of early puberty. Follow-up over 
2 years showed improved predicted adult height, but as of this date, 
no data have been published to document actual adult heights19. 
A proof-of-concept trial demonstrated that co-administration 
of growth hormone plus an aromatase inhibitor (again, alongside 
standard steroid replacement) improved adult height in a single 
adolescent male patient with CAH20.
Since normal adult height may be achieved through judicious use 
of standard GC and MC therapies, further long-term prospective 
randomized and carefully controlled studies are needed to deter-
mine whether the use of growth-promoting drugs is safe and 
cost-effective in individuals with CAH. At present, such treatments 
are not considered standard care in children with CAH.
Other medical strategies
Reducing adrenocorticotropic hormone (ACTH) production is 
another mechanism for minimizing adrenal androgen excess. 
In a small trial of eight women with classic CAH, the selective 
corticotropin-releasing hormone receptor type 1 antagonist, NBI-
77860, was added to conventional therapy21, resulting in a more 
than 40% reduction in the morning ACTH surge and about 27% 
lower serum 17OHP. Variable reductions of androstenedione and 
testosterone were observed.
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Mitotane, a different type of adrenolytic used for treatment of 
adrenocortical cancer and Cushing syndrome, was administered 
to a man with classic CAH and testicular adrenal rest tumors 
(TARTs) who was infertile for 2 years22. Adrenal androgen 
precursors were suppressed and TARTs regressed. Paternity was 
achieved following an increase in sperm count. Mitotane is a 
potential teratogen (pregnancy category D) and induces CYP3A4, 
increasing GC clearance, and therefore is not considered a useful 
adjunct to CAH therapy. ATR-101 (ClinicalTrials.gov Identifier: 
NCT02804178), which inhibits acyl co-A cholesterol acyl-
transferase and shares some mechanisms with mitotane23–25, 
has been tested in adults with classic CAH; results of this trial 
have not yet been published.
Adrenalectomy
Adrenalectomy reduces virilization in females and permits 
decreased GC doses but this is considered a rather radical approach 
because of surgical risk. Moreover, there is an increased risk of 
life-threatening adrenal crisis with absolute dependence on exog-
enous hormone replacement and loss of potentially beneficial 
hormones—for example, dehydroepiandrosterone (DHEA) and 
epinephrine—from the adrenal medulla. A final consideration 
is that adrenalectomy may inadvertently cause the development 
of gonadal adrenal rest tumors that secrete androgens26,27. For 
these reasons, the initial enthusiasm has been tempered by 
long-term complications. Individuals who are known to be non- 
adherent are poor candidates for adrenalectomy. A systematic 
review of bilateral adrenalectomy in CAH28 identified 48 cases 
ranging from infancy to adulthood and most were carried out for 
uncontrolled androgen excess or iatrogenic Cushing syndrome 
(or both) caused by administration of large GC doses to achieve 
control. Post-operative amelioration of these symptoms was 
noted in most patients, including three women who were able 
to conceive following adrenalectomy. In contrast, about 40% 
of patients experienced adverse outcomes, including eight 
patients with adrenal crisis and one death in an infant. Five 
males developed adrenal rest tumors requiring surgical removal. 
Unexpectedly, two males had regression of TARTs28. The 
conclusion from this review is that adrenalectomy is effective 
for relief of refractory adrenal androgen excess, but that candi-
dates for adrenalectomy must be chosen judiciously and educated 
extensively regarding post-operative risks.
Epinephrine deficiency
Individuals with classic CAH have adrenomedullary insufficiency 
because GCs are required for development and regulation of the 
adrenal medulla29. The physiologic responses of glucose, insulin, 
and leptin pathways are dysregulated during exercise among 
adolescent patients lacking both cortisol and epinephrine30,31. 
The clinical implications of epinephrine deficiency are not 
fully known, but it may contribute to hypoglycemia during 
febrile illnesses, especially in young children, and impair the 
response to stress32,33. Decreased epinephrine production has been 
observed in newborns with classic CAH compared with controls; 
norepinephrine levels were similar32. Epinephrine replacement or 
supplementation has not been studied. It is not known whether 
a compensatory norepinephrine response is sufficient.
Gene therapy
In two decades since the initial report that adenoviral gene ther-
apy transiently restored enzyme activity in a mouse model of 
21-hydroxylase deficiency34, there have been no human trials. 
Animal research is ongoing, and intravenous injection of an 
adenoviral-Cyp21a1 vector in such mice allowed functional 
enzyme expression in adrenal tissue, resulting in weight gain, near 
normal progesterone levels, and improved stress response for more 
than 15 weeks35. However, in another laboratory setting, the 
therapeutic effect lasted only 8 weeks36. Auto-transplantation of 
Cyp21a1-expressing fibroblasts into 21-hydroxylase–deficient 
mouse subcutaneous tissue or direct injection of adenovirus-
Cyp21a1 constructs into mouse muscle demonstrated enzyme 
efficacy for about 4 weeks37. Thus, both adrenal and extra- 
adrenal induction of Cyp21a1 can temporarily ameliorate steroid 
metabolism in 21-hydroxylase null mice. It is unclear whether 
the murine data will be translated into effective human treat-
ments. Permanent correction of mutations causing CAH with 
gene therapy directed at a patient’s own adrenal stem cells would 
theoretically cure CAH and supplant imperfect steroid replace-
ment. Cell-based therapies and gene-editing technology now 
in development may be options for disease cure in the future38.
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